Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03520257 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus

Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

This study uses to suppress the growth of tumors, extend the patient's survival time and improve the quality of life as much as possible. Through the treatment, the patient is given the chance to undergo surgical resection, thereby more effectively prolonging the OS. Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR and exerting anti-angiogenic effects. Preclinical studies have shown that its anti-tumor effect is better than that of the similar drug PTK787. Phase II studies of hepatocellular carcinoma have initially demonstrated the effectiveness and safety of apatinib in the treatment of advanced HCC. Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities. Based on the therapeutic potential of apatinib and radiotherapy, we designed a prospective exploratory clinical study of this patient with advanced liver cancer.

NCT ID: NCT03519997 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Start date: April 26, 2018
Phase: Phase 2
Study type: Interventional

This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.

NCT ID: NCT03518502 Recruiting - Clinical trials for Hepatocellular Carcinoma

Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

Start date: March 1, 2012
Phase: Phase 4
Study type: Interventional

Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be beneficial for controlling intrahepatic tumour. The investigators aimed to compare the efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC patients with EHM.

NCT ID: NCT03517488 Not yet recruiting - Melanoma Clinical Trials

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

DUET-2
Start date: August 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

NCT ID: NCT03517332 Recruiting - Breast Cancer Clinical Trials

Circulating Tumor DNA Exposure in Peripheral Blood

Start date: January 1, 2015
Phase:
Study type: Observational

This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

NCT ID: NCT03516890 Completed - Clinical trials for Hepatocellular Carcinoma

Management of Spontaneous Ruptured Hepatocellular Carcinoma

Start date: January 1, 2005
Phase:
Study type: Observational

To investigate the best treatment for hepatocellular carcinoma rupture

NCT ID: NCT03516448 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Expanding Phase III Study of Tyroserleutide for Injection

Start date: March 24, 2016
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups´╝Ü6mg/d Tyroserleutide (injection), or placebo

NCT ID: NCT03515369 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

Start date: May 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the effect of traditional Chinese medicine Babaodan on tumor recurrence of hepatocellular carcinoma after curative resection, as well as the safety of this treatment

NCT ID: NCT03511703 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

This study uses to suppress the growth of tumors, extend the patient's survival time and improve the quality of life as much as possible. Through the treatment, the patient is given the chance to undergo surgical resection, thereby more effectively prolonging the OS. Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR and exerting anti-angiogenic effects. Preclinical studies have shown that its antitumor effect is better than that of the similar drug PTK787. Phase II studies of hepatocellular carcinoma have initially demonstrated the effectiveness and safety of apatinib in the treatment of advanced HCC. TACE embolized tumor artery blood supply to inhibit tumor growth and shrink tumors. Based on the therapeutic potential of apatinib, and TACE in their respective tumors, we designed a prospective exploratory clinical study of this patient with advanced liver cancer.

NCT ID: NCT03511222 Not yet recruiting - Gastric Cancer Clinical Trials

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Start date: July 31, 2018
Phase: Phase 1
Study type: Interventional

The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.